# Adaptimmune Therapeutics PLC: overview ADAPY · OTC · CIK 1621227 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/adapy.md) · [Financials](/companies/adapy/financials.md) · [Filings](/companies/adapy/filings.md) · [Insiders](/companies/adapy/insiders.md) Latest reported revenue: [$13.7m](/filings/0001558370-25-011307.md) for Q2 FY2025, three months to 2025-06-30, from the 10-Q filed Aug 13, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001558370-25-011307). ## Last eight quarters | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.3](/filings/0001558370-24-015532.md) | [0.2 d](/filings/0001558370-25-003544.md) | [5.7](/filings/0001558370-25-007571.md) | [128](/filings/0001558370-25-011307.md) | [40.9](/filings/0001558370-24-015532.md) | [3.2 d](/filings/0001558370-25-003544.md) | [7.3](/filings/0001558370-25-007571.md) | [13.7](/filings/0001558370-25-011307.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(637.1%)](/filings/0001558370-24-015532.md) | [(21582.7%) d](/filings/0001558370-25-003544.md) | [(867.6%)](/filings/0001558370-25-007571.md) | [53.6%](/filings/0001558370-25-011307.md) | [(35.9%)](/filings/0001558370-24-015532.md) | [(2281.8%) d](/filings/0001558370-25-003544.md) | [(627.8%)](/filings/0001558370-25-007571.md) | [(221.5%)](/filings/0001558370-25-011307.md) | | Net margin | % | [(623.0%)](/filings/0001558370-24-015532.md) | [(20743.3%) d](/filings/0001558370-25-003544.md) | [(854.2%)](/filings/0001558370-25-011307.md) | [54.2%](/filings/0001558370-25-011307.md) | [(43.1%)](/filings/0001558370-24-015532.md) | [(2303.4%) d](/filings/0001558370-25-003544.md) | [(653.2%)](/filings/0001558370-25-011307.md) | [(221.8%)](/filings/0001558370-25-011307.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [0.04](/filings/0001558370-25-011307.md) | [(0.01)](/filings/0001558370-24-015532.md) | not reported | [(0.03)](/filings/0001558370-25-007571.md) | [(0.02)](/filings/0001558370-25-011307.md) | | Free cash flow | $m | [(45.4) d](/filings/0001558370-24-015532.md) | [(15.5) d](/filings/0001558370-25-003544.md) | [(32.1)](/filings/0001558370-25-007571.md) | [47.0 d](/filings/0001558370-25-011307.md) | [(54.6) d](/filings/0001558370-24-015532.md) | [(34.4) d](/filings/0001558370-25-003544.md) | [(67.8)](/filings/0001558370-25-007571.md) | [(34.9) d](/filings/0001558370-25-011307.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.0](/filings/0001558370-23-002907.md) | [6.1](/filings/0001558370-24-002537.md) | [27.1](/filings/0001558370-25-003544.md) | [60.3](/filings/0001558370-25-003544.md) | [178](/filings/0001558370-25-003544.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(3370.5%)](/filings/0001558370-23-002907.md) | [(2638.6%)](/filings/0001558370-24-002537.md) | [(604.0%)](/filings/0001558370-25-003544.md) | [(231.8%)](/filings/0001558370-25-003544.md) | [(38.6%)](/filings/0001558370-25-003544.md) | | Net margin | % | [(3286.8%)](/filings/0001558370-23-002907.md) | [(2571.0%)](/filings/0001558370-24-002537.md) | [(609.5%)](/filings/0001558370-25-003544.md) | [(188.9%)](/filings/0001558370-25-003544.md) | [(39.8%)](/filings/0001558370-25-003544.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001558370-23-002907.md) | [(0.17)](/filings/0001558370-24-002537.md) | [(0.17)](/filings/0001558370-25-003544.md) | [(0.09)](/filings/0001558370-25-003544.md) | [(0.05)](/filings/0001558370-25-003544.md) | | Free cash flow | $m | [(55.9)](/filings/0001558370-23-002907.md) | [2.2](/filings/0001558370-24-002537.md) | [(171)](/filings/0001558370-25-003544.md) | [(146)](/filings/0001558370-25-003544.md) | [(74.1)](/filings/0001558370-25-003544.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/adapy/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) None of the funds in coverage reports a position in its latest 13F. ## Recent filings [All 804 filings](/companies/adapy/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2025-10-20 | 07:50 ET | [8-K](/filings/0001104659-25-100618.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-100618 | | 2025-09-26 | 16:30 ET | [8-K](/filings/0001104659-25-093882.md) | 3.01 Delisting notice | 0001104659-25-093882 | | 2025-09-12 | 16:27 ET | [8-K](/filings/0001104659-25-089558.md) | 3.01 Delisting notice | 0001104659-25-089558 | | 2025-09-08 | 16:05 ET | [8-K](/filings/0001558370-25-011925.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001558370-25-011925 | | 2025-08-29 | 16:30 ET | [8-K](/filings/0001558370-25-011820.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001558370-25-011820 | | 2025-08-19 | 18:53 ET | [SCHEDULE 13D/A](/filings/0001072613-25-000670.md) | Ownership report, active investor, amended | 0001072613-25-000670 | | 2025-08-15 | 16:30 ET | [8-K](/filings/0001558370-25-011616.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001558370-25-011616 | | 2025-08-14 | 16:31 ET | [8-K](/filings/0001558370-25-011579.md) | 3.01 Delisting notice | 0001558370-25-011579 | | 2025-08-13 | 07:47 ET | [10-Q](/filings/0001558370-25-011307.md) | Quarterly report, period 2025-06-30 | 0001558370-25-011307 | | 2025-08-13 | 07:37 ET | [8-K](/filings/0001558370-25-011304.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001558370-25-011304 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2024](/filings/0001558370-25-003544.md), filed Mar 24, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1621227 - Tickers: ADAPY - Exchange: OTC - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: X0 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.